EOS imaging Announces New Studies Highlighting Clinical Advantages of 3D Imaging for Lower Limb Orthopedic Care

Regulatory News:

EOS Imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced that two new peer-reviewed studies highlight the clinical advantages of the EOS 2D/3D imaging system in diagnosis and treatment planning for lower limb and hindfoot orthopedic care. The studies, which demonstrate the benefit of 3D images generated by the EOS system compared to traditional CT and X-ray scans, were published in November in the American Journal of Roentgenology and Skeletal Radiology.

Both studies were performed by radiologists at the Balgrist University Hospital in Zurich, Switzerland, one of the most recognized institutions worldwide in musculoskeletal imaging. The first study showed that femoral and tibial torsion measurements taken with the EOS system were comparable to those obtained with CT scan, which is considered the standard imaging modality for lower limb torsional assessment¹.

Dr. Florian Buck, who led the clinical study, commented, "EOS achieved this level of precision with a radiation dose that is significantly lower than that of CT scan. This result now opens the way to a switch to EOS for these torsion exams.”

The second study concluded that 3D hindfoot alignment measurements from the EOS system were substantially more precise than standard X-ray measurements, and suggests 3D scanning may help meet the clinical challenge of accurately assessing and treating hindfoot abnormalities.²

The EOS imaging system is the first and only full body, low dose 3D imaging technology available for orthopedic care and is currently being featured at RSNA.

Marie Meynadier, CEO of EOS imaging, said, "The strong interest in our low dose 3D imaging technology at the RSNA meeting reinforces our growing momentum in the U.S. and Europe and our increasing footprint in Asia over the past year. These new clinical results add to the substantial body of clinical evidence supporting the EOS benefits and helping to generate this momentum.”

For more information, please visit www.eos-imaging.com.

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Thanks to an installed base of 51 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people, including an R&D team of 21 engineers, and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: www.eos-imaging.com.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2012 annual revenue on 21 January 2013 (after market).

¹ FM Buck et al. Femoral and Tibial Torsion Measurements With 3D Models Based on Low-Dose Biplanar Radiographs in Comparison With Standard CT Measurements. AJR 2012; 199:W607-W612.

² R Sutter et al. Three-dimensional hindfoot alignment measurements based on biplanar radiographs: comparison with standard radiographic measurements. Skeletal Radiol 2012.